These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23407550)

  • 1. Optimal use of bisphosphonates in patients with multiple myeloma.
    Terpos E; Roodman GD; Dimopoulos MA
    Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
    [No Abstract]   [Full Text] [Related]  

  • 2. [Integrated supportive therapy for multiple myeloma-bone disease treatment, myeloma kidney treatment, cryotherapy, nutrition support team].
    Miwa A
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():603-27. PubMed ID: 23134022
    [No Abstract]   [Full Text] [Related]  

  • 3. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
    Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A
    Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
    Ural AU; Avcu F
    Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
    [No Abstract]   [Full Text] [Related]  

  • 7. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.
    Kleber M; Udi J; Metzke B; Terpos E; Roodmann GD; Morgan G; Dispenzieri A; Einsele H; Wäsch R; Engelhardt M
    Leuk Lymphoma; 2012 Jun; 53(6):1057-61. PubMed ID: 22149167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].
    García-Sanz R; Alegre A; Capote FJ; Hernández JM; Rosiñol L; Rubia Jde L; Sureda A; Arriba Fd; Bargay J; Díaz Mediavilla J; García-Laraña J; Lahuerta JJ; Mateos MV; Prósper F; San Miguel J; Bladé J;
    Med Clin (Barc); 2010 Mar; 134(6):268-78. PubMed ID: 19863972
    [No Abstract]   [Full Text] [Related]  

  • 10. Denosumab for bone lesions in multiple myeloma - what is its value?
    Goldstein DA
    Haematologica; 2018 May; 103(5):753-754. PubMed ID: 29712820
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of bisphosphonates in multiple myeloma.
    Levy J; Roodman GD
    Curr Hematol Malig Rep; 2009 Apr; 4(2):108-12. PubMed ID: 20425422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology and treatment of myeloma related bone disease.
    Terpos E; Christoulas D; Gavriatopoulou M
    Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Disease in Myeloma: The Claws of CRAB.
    Fonseca R; Jain T
    Clin Cancer Res; 2016 Mar; 22(6):1301-3. PubMed ID: 26792259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloma: diagnosis complications and supportive care.
    Morgan G
    Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
    Lund T; Gundesen MT; Juul Vangsted A; Helleberg C; Haukås E; Silkjær T; Asmussen JT; Manuela Teodorescu E; Amdi Jensen B; Schmidt Slørdahl T; Nahi H; Waage A; Abildgaard N; Schjesvold F;
    Blood Cancer J; 2024 Apr; 14(1):65. PubMed ID: 38622134
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Morgan GJ; Davies FE; Gregory WM; Szubert AJ; Bell SE; Drayson MT; Owen RG; Ashcroft AJ; Jackson GH; Child JA;
    Blood; 2012 Jun; 119(23):5374-83. PubMed ID: 22498739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
    Sanders J; Crawford B; Gibson J; Joy Ho P; Iland H; Joshua D
    Int J Lab Hematol; 2007 Oct; 29(5):395-7. PubMed ID: 17824924
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic approaches to myeloma bone disease: an evolving story.
    Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
    Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.